Research
Publications
Two decades of work on metabolic disease, inflammation, oncology and AI-driven drug discovery, in papers, preprints and patents.
Find me elsewhere
- Google ScholarFull list with citation counts
- ResearchGatePapers, full texts and questions
- LinkedInCurrent work and writing
- 698citations
- 16h-index
- 17i10-index
Citation figures are from Google Scholar as of October 2026. Preprints and duplicate records are listed once. Names in bold are mine.
Journal articles 22
2026
AI-driven discovery and validation of a GIPC1 PDZ domain inhibitor for pancreatic ductal adenocarcinoma
Rachamala HK, Rao Nakka NM, Angom RS, Varanasi SM, Wei F, Kulkarni T, Dutta SK, Wang E, Kulkarni NM, Ben Geoffrey AS, Hegde SP, Perumal S, Gurram K, Gharibi H, Gaetani M, Mukherjee SP, Babiker H, Pal K, Mukhopadhyay D
Cell Reports 45(8):117777. doi:10.1016/j.celrep.2026.117777
2025
Molecular Glue-Design-Evaluator (MOLDE): an advanced method for in-silico molecular glue design
Ben Geoffrey AS, Agrawal D, Kulkarni NM, Gunasekaran M
ACS Omega 10(7):6650-6662. doi:10.1021/acsomega.4c08049
Correction to “Molecular Glue-Design-Evaluator (MOLDE): an advanced method for in-silico molecular glue design”
Ben Geoffrey AS, Agrawal D, Kulkarni NM, Gunasekaran M
ACS Omega 10(21):22296. doi:10.1021/acsomega.5c01516
2024
PROTAC-Design-Evaluator (PRODE): an advanced method for in-silico PROTAC design
Ben Geoffrey AS, Agrawal D, Kulkarni NM, Vetrivel R, Gurram K
ACS Omega 9(11):12611-12621. doi:10.1021/acsomega.3c07318
2021
STE20-type protein kinase MST4 controls NAFLD progression by regulating lipid droplet dynamics and metabolic stress in hepatocytes
Caputo M, Cansby E, Kumari S, Kurhe Y, Nair S, Ståhlman M, Kulkarni NM, Borén J, Marschall H, Blüher M, Mahlapuu M
Hepatology Communications 5(7):1183-1200. doi:10.1002/hep4.1702
2020
Depletion of protein kinase STK25 ameliorates renal lipotoxicity and protects against diabetic kidney disease
Cansby E, Caputo M, Gao L, Kulkarni NM, Nerstedt A, Ståhlman M, Borén J, Porosk R, Soomets U, Pedrelli M, Parini P, Marschall HU, Nyström J, Howell BW, Mahlapuu M
JCI Insight 5(24):e140483. doi:10.1172/jci.insight.140483
High fat worsens olanzapine induced metabolic abnormalities in rats
Jamaluddin SJ, Nilugal KC, Kulkarni NM, Fattepur S, Abdullah I, Ugandar RE
British Food Journal 122(10):3065-3075. doi:10.1108/bfj-02-2020-0121
2019
Protein kinase MST3 modulates lipid homeostasis in hepatocytes and correlates with nonalcoholic steatohepatitis in humans
Cansby E, Kulkarni NM, Magnusson E, Kurhe Y, Amrutkar M, Nerstedt A, Ståhlman M, Sihlbom C, Marschall H, Borén J, Blüher M, Mahlapuu M
The FASEB Journal 33(9):9974-9989. doi:10.1096/fj.201900356rr
Targeted delivery of Stk25 antisense oligonucleotides to hepatocytes protects mice against nonalcoholic fatty liver disease
Cansby E, Nuñez-Durán E, Magnusson E, Amrutkar M, Booten SL, Kulkarni NM, Svensson LT, Borén J, Marschall HU, Aghajan M, Mahlapuu M
Cellular and Molecular Gastroenterology and Hepatology 7(3):597-618. doi:10.1016/j.jcmgh.2018.12.004
2018
STK25 regulates oxidative capacity and metabolic efficiency in adipose tissue
Sütt S, Cansby E, Paul A, Amrutkar M, Nuñez-Durán E, Kulkarni NM, Ståhlman M, Borén J, Laurencikiene J, Howell BW, Enerbäck S, Mahlapuu M
Journal of Endocrinology 238(3):187-202. doi:10.1530/joe-18-0182
2017
Terminalia chebula Retz. – an important medicinal plant
Kolla JN, Kulkarni NM, Kura RR, Theepireddy SKR
Herba Polonica 63(4):45-56. doi:10.1515/hepo-2017-0024
Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines
Nidhyanandan S, Thippeswamy BS, Chandrasekhar KB, Reddy ND, Kulkarni NM, Karthikeyan K, Khan FR, Raghul J, Vijaykanth G, Narayanan S
Anti-Cancer Drugs 28(9):1002-1017. doi:10.1097/cad.0000000000000544
2016
Altered pharmacokinetics of rosiglitazone in a mouse model of non-alcoholic fatty liver disease
Kulkarni NM, Malampati S, Mahat MYA, Chandrasekaran S, Raghul J, Khan AA, Krishnan UM, Narayanan S
Drug Metabolism and Personalized Therapy 31(3):165-171. doi:10.1515/dmpt-2016-0008
Subacute toxicity of gallic acid, isolated from Terminalia chebula, in Swiss albino mice
Theepireddy DMSKR, Kulkarni NM, Chinthala R, et al.
International Journal of Chemistry and Pharmaceutical Sciences 4(10):439-443.
2015
Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo
Nidhyanandan S, Boreddy TS, Chandrasekhar KB, Reddy ND, Kulkarni NM, Narayanan S
European Journal of Pharmacology 764:508-519. doi:10.1016/j.ejphar.2015.07.048
A novel animal model of metabolic syndrome with non-alcoholic fatty liver disease and skin inflammation
Kulkarni NM, Jaji MS, Shetty P, Kurhe YV, Chaudhary S, Vijaykant G, Raghul J, Vishwakarma SL, Rajesh BN, Mookkan J, Krishnan UM, Narayanan S
Pharmaceutical Biology 53(8):1110-1117. doi:10.3109/13880209.2014.960944
Topical atorvastatin ameliorates 12-O-tetradecanoylphorbol-13-acetate induced skin inflammation by reducing cutaneous cytokine levels and NF-κB activation
Kulkarni NM, Muley MM, Jaji MS, Vijaykanth G, Raghul J, Reddy NKD, Vishwakarma SL, Rajesh NB, Mookkan J, Krishnan UM, Narayanan S
Archives of Pharmacal Research 38(6):1238-1247. doi:10.1007/s12272-014-0496-0
2014
Combination of vildagliptin and rosiglitazone ameliorates nonalcoholic fatty liver disease in C57BL/6 mice
Mookkan J, De S, Shetty P, Kulkarni NM, Devisingh V, Jaji MS, Lakshmi V, Chaudhary S, Kulathingal J, Rajesh N, Narayanan S
Indian Journal of Pharmacology 46(1):46. doi:10.4103/0253-7613.125166
2011
Embelin reduces cutaneous TNF-α level and ameliorates skin edema in acute and chronic model of skin inflammation in mice
Kumar GK, Dhamotharan R, Kulkarni NM, Mahat MYA, Gunasekaran J, Ashfaque M
European Journal of Pharmacology 662(1-3):63-69. doi:10.1016/j.ejphar.2011.04.037
Embelin ameliorates dextran sodium sulfate-induced colitis in mice
Kumar GK, Dhamotharan R, Kulkarni NM, Honnegowda S, Murugesan S
International Immunopharmacology 11(6):724-731. doi:10.1016/j.intimp.2011.01.022
2010
Modulation of the cyclooxygenase pathway via inhibition of nitric oxide production contributes to the anti-inflammatory activity of kaempferol
Mahat MYA, Kulkarni NM, Vishwakarma SL, Khan FR, Thippeswamy BS, Hebballi V, Adhyapak AA, Benade VS, Ashfaque SM, Tubachi S, Patil BM
European Journal of Pharmacology 642(1-3):169-176. doi:10.1016/j.ejphar.2010.05.062
2006
Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain
Patil BM, Kulkarni NM, Unger BS
European Journal of Pharmacology 551(1-3):112-115. doi:10.1016/j.ejphar.2006.09.009
Preprints 3
DMPKformer: an interpretable multimodal deep learning framework for reliable ADMET property prediction
Singh A, Kanchan S, Anapat S, Gurram K, Kulkarni NM, Ben Geoffrey AS
bioRxiv (preprint). doi:10.64898/2026.05.28.728612
An in-silico approach for novel molecular glue design by rationalizing known molecular glue mediated ternary complex formation
Ben Geoffrey AS, Kulkarni NM, Agrawal D, Bharti N, Vetrivel R, Gurram K
bioRxiv (preprint), 2022.10.04.510266. doi:10.1101/2022.10.04.510266
A new in-silico approach for PROTAC design and quantitative rationalization of PROTAC mediated ternary complex formation
Ben Geoffrey AS, Kulkarni NM, Agrawal D, Vetrivel R, Gurram K
bioRxiv (preprint), 2022.07.11.499663. doi:10.1101/2022.07.11.499663
Patents 2
Formulation and a method of treating carcinoma
Kulkarni N, Baskaran B, Samraj BGA, Bhagavat R, Gurram K, et al.
US Patent Application 19/366,141.
Inhibitors of ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP-1)
Ramanarayanan GBV, Saravanan P, Saravanan V, Nagaraj K
WO Patent WO2024127343A1.
Chapters, abstracts and thesis 7
Metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and psoriasis
Kulkarni NM, Krishnan UM, Narayanan S
In: Liver Disease: Diagnosis, Treatment and Management, pp. 45-72, 2016 (chapter).
Development of a new rat model of non-alcoholic fatty liver disease with insulin resistance and obesity
Narayanan S, Jaji MS, Devisingh V, Kulkarni NM, Navinrajesh B, et al.
Diabetes 61:A270, 2012 (abstract).
Effect of BLX-1002 in a rat model of non-alcoholic fatty liver disease
Mookkan J, Kulathingal J, Jaji MS, Devisingh V, Kulkarni NM, et al.
Diabetes 61:A250, 2012 (abstract).
Combination of vildagliptin and rosiglitazone ameliorates non-alcoholic fatty liver disease in C57BL/6 mice
Mookkan J, De S, Shetty P, Kulkarni NM, Devisingh V, Jaji MS, et al.
Diabetes 60:A284, 2011 (abstract).
Effect of BLX 1002 on key features of non-alcoholic fatty liver disease (NAFLD) in animal models
Narayanan S, Devisingh V, Kulkarni NM, Shetty P, Jaji MS, Rajesh BN, et al.
Diabetes 60:A288-A289, 2011 (abstract).
Efficacy of BLX 1002 in animal models of non-alcoholic fatty liver disease and dyslipidemia
Narayanan S, Vijayaraj D, Kulkarni NM, Shetty P, Jayanarayan K, et al.
Journal of Hepatology 54:S502, 2011 (abstract).
Effect of atypical antipsychotics on hypertension and insulin resistance in fructose fed rats
Kulkarni N
Rajiv Gandhi University of Health Sciences, Bangalore, 2006 (thesis).
Looking for a paper?
If a paper is behind a paywall, ask me for a copy by email or find the full text on ResearchGate.